Astellas Pharma (OTCMKTS:ALPMY) Downgraded by Zacks Investment Research

Astellas Pharma (OTCMKTS:ALPMY) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Monday, Zacks.com reports.

According to Zacks, “Astellas Pharma, Inc. is engaged in the research, development, manufacturing and marketing of pharmaceuticals drugs. Products offered by the Company include Prograf applicable for the prevention of rejection in organ transplants, Vesicare for treatment of overactive bladder, Protopic for the treatment of atopic dermatitis in the topical immunomodulator class, Harnal to treat the functional symptoms of benign prostatic hyperplasia (BPH), including weak urinary stream, frequent nighttime urination, and sensation of incomplete emptying of the bladder and Fungard an antifungal agent. Astellas Pharma, Inc. is headquartered in Tokyo, Japan. “

OTCMKTS ALPMY opened at $15.15 on Monday. The business’s 50-day moving average price is $15.47 and its 200 day moving average price is $15.52. Astellas Pharma has a twelve month low of $13.41 and a twelve month high of $18.43. The company has a market capitalization of $28.21 billion, a PE ratio of 21.96 and a beta of 0.63.

Astellas Pharma (OTCMKTS:ALPMY) last released its earnings results on Tuesday, April 27th. The company reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.22 by ($0.28). Astellas Pharma had a return on equity of 13.24% and a net margin of 11.03%. Sell-side analysts predict that Astellas Pharma will post 1.28 EPS for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant.

Further Reading: Do equity income investments outperform growth and income investments?

Get a free copy of the Zacks research report on Astellas Pharma (ALPMY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.